Biliverdin administration protects against endotoxin-induced acute lung injury in rats.
Given the high morbidity and mortality rates associated with pulmonary inflammation in sepsis, there is a pressing need for new therapeutic modalities to prevent acute respiratory distress. The enzyme heme oxygenase-1 (HO-1) provides potent cytoprotection against lung injury; however, the mechanism by which it does so is unclear. HO-1 catabolizes heme into biliverdin (BV), which is rapidly converted to bilirubin by BV reductase. We tested the hypothesis that BV administration could substitute for the effects observed with HO-1. Using the well-described rat model of LPS-induced shock, we demonstrate that exposure to BV imparts a potent defense against lethal endotoxemia systemically, as well as in the lungs, and effectively abrogates the inflammatory response. BV administration before a lethal dose of LPS leads to a significant improvement in long-term survival: 87% vs. 20% in sham-treated controls. BV treatment suppressed LPS-induced increases in lung permeability and lung alveolitis and significantly reduced serum levels of the LPS-induced proinflammatory cytokine IL-6. Moreover, bilirubin administered just after LPS also abrogated lung inflammation. BV treatment also augmented expression of the anti-inflammatory cytokine IL-10. Similar effects on production were observed with BV treatment in vitro in mouse lung endothelial cells and RAW 264.7 macrophages treated with LPS. In conclusion, these data demonstrate that BV can modulate the inflammatory response and suppress pathophysiological changes in the lung and may therefore have therapeutic application in inflammatory disease states of the lung.
Sarady-Andrews
Judit K
JK
Harvard Medical School, Beth Israel Deaconess Medical Center, 99 Brookline Avenue, Ste. 370G, Boston, MA 02215, USA.
Liu
Fang
F
Gallo
David
D
Nakao
Atsunori
A
Overhaus
Marcus
M
Ollinger
Robert
R
Choi
Augustine M
AM
Otterbein
Leo E
LE
D000818:Animals; D001664:Biliverdine / Q000008:administration & dosage*; D002199:Capillary Permeability / Q000187:drug effects; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D051547:Heme Oxygenase-1 / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity*; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D055370:Lung Injury; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D008297:Male; D011014:Pneumonia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012772:Shock, Septic / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013995:Time
D015850:Interleukin-6; D008070:Lipopolysaccharides; D016753:Interleukin-10; D051547:Heme Oxygenase-1; D001664:Biliverdine